Platelet-derived CD154: Ultrastructural Localization and Clinical Correlation in Organ Transplantation

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2012 Sep 6

PMID 22947105

Citations 10

Authors

A H Charafeddine

E J Kim

D M Maynard

H Yi

T A Weaver

M Gunay-Aygun

M Russell

W A Gahl

A D Kirk

Affiliations

Soon will be listed here.

Abstract

CD154 is an immunostimulatory ligand for CD40 that markedly influences alloimmunity. Its presence in platelets suggests that its release and subsequent immune effects are driven by trauma and thus could be relevant following organ transplantation. However, the release of platelet derived CD154 and its consequences have not been investigated in a clinical transplant setting. To better characterize the relationship between platelet activation and CD154 release, we investigated CD154 release by platelets obtained from normal individuals, and patients with two genetic defects that influence platelet granule development. Using these unique patient populations and immune-electron microscopy, we confirmed that CD154 was an alpha granule and not a cell surface protein, and thereafter optimized the methods for its in vivo measurement in humans. We then investigated plasma CD154 levels in kidney and liver transplant recipients and found no evidence that CD154 levels fluctuated systemically as a result of kidney or liver transplant procedures. Paradoxically, we found that kidney transplant patients had significantly lower systemic CD154 levels during episodes of rejection. These data suggest that the immune effects of CD154 are likely mediated through local and not systemic mechanisms, and discourage the use of CD154 as a peripheral biomarker in organ transplantation.

Citing Articles

A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiology.

Akbari P, Vuckovic D, Stefanucci L, Jiang T, Kundu K, Kreuzhuber R Nat Commun. 2023; 14(1):5023.

PMID: 37596262 PMC: 10439125. DOI: 10.1038/s41467-023-40679-y.

Platelets as Mediators of Neuroinflammation and Thrombosis.

Rawish E, Nording H, Munte T, Langer H Front Immunol. 2020; 11:548631.

PMID: 33123127 PMC: 7572851. DOI: 10.3389/fimmu.2020.548631.

Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome.

Grosdidier C, Blanz K, Deharo P, Bernot D, Poggi M, Bastelica D Res Pract Thromb Haemost. 2019; 3(4):684-694.

PMID: 31624788 PMC: 6781928. DOI: 10.1002/rth2.12244.

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Kean L, Turka L, Blazar B Immunol Rev. 2017; 276(1):192-212.

PMID: 28258702 PMC: 5338458. DOI: 10.1111/imr.12523.

Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases.

Middleton E, Weyrich A, Zimmerman G Physiol Rev. 2016; 96(4):1211-59.

PMID: 27489307 PMC: 6345245. DOI: 10.1152/physrev.00038.2015.

References

King S, Reed G . Development of platelet secretory granules. Semin Cell Dev Biol. 2002; 13(4):293-302. DOI: 10.1016/s1084952102000599. View

Kamykowski J, Carlton P, Sehgal S, Storrie B . Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet α-granules. Blood. 2011; 118(5):1370-3. DOI: 10.1182/blood-2011-01-330910. View

Reed G, Fitzgerald M, Polgar J . Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood. 2000; 96(10):3334-42. View

Xu H, Arnaud F, Tadaki D, Burkly L, Harlan D, Kirk A . Human platelets activate porcine endothelial cells through a CD154-dependent pathway. Transplantation. 2001; 72(11):1858-61. DOI: 10.1097/00007890-200112150-00029. View

Nurden A, Nurden P . The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2006; 21(1):21-36. DOI: 10.1016/j.blre.2005.12.003. View

Ahn E, Lander G, Jy W, Bidot C, Jimenez J, Horstman L . Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004; 114(2):143-8. DOI: 10.1016/j.thromres.2004.06.005. View

Weber M, Rabenau B, Stanisch M, Nef H, Mollmann H, Elsasser A . Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res. 2007; 120(6):811-4. DOI: 10.1016/j.thromres.2007.01.014. View

Lederman S, Yellin M, Krichevsky A, BELKO J, Lee J, Chess L . Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992; 175(4):1091-101. PMC: 2119166. DOI: 10.1084/jem.175.4.1091. View

Reed G . Platelet secretory mechanisms. Semin Thromb Hemost. 2004; 30(4):441-50. DOI: 10.1055/s-2004-833479. View

10.

van Kooten C, Banchereau J . CD40-CD40 ligand. J Leukoc Biol. 2000; 67(1):2-17. DOI: 10.1002/jlb.67.1.2. View

11.

Kirk A, Harlan D, Armstrong N, Davis T, Dong Y, GRAY G . CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997; 94(16):8789-94. PMC: 23132. DOI: 10.1073/pnas.94.16.8789. View

12.

White J . The dense bodies of human platelets. Origin of serotonin storage particles from platelet granules. Am J Pathol. 1968; 53(5):791-808. PMC: 2013516. View

13.

Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P . Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem. 2010; 43(7-8):666-70. DOI: 10.1016/j.clinbiochem.2009.12.021. View

14.

Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S . The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993; 72(2):291-300. DOI: 10.1016/0092-8674(93)90668-g. View

15.

Gauchat J, Henchoz S, Mazzei G, Aubry J, Brunner T, Blasey H . Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993; 365(6444):340-3. DOI: 10.1038/365340a0. View

16.

Kirk A, Blair P, Tadaki D, Xu H, Harlan D . The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci. 2001; 356(1409):691-702. PMC: 1088456. DOI: 10.1098/rstb.2001.0855. View

17.

Kirk A, Burkly L, Batty D, Baumgartner R, Berning J, Buchanan K . Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999; 5(6):686-93. DOI: 10.1038/9536. View

18.

Crist S, Sprague D, Ratliff T . Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood. 2008; 111(7):3553-61. PMC: 2275021. DOI: 10.1182/blood-2007-05-088161. View

19.

Ivandic B, Spanuth E, Haase D, Lestin H, Katus H . Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007; 53(7):1231-4. DOI: 10.1373/clinchem.2007.085332. View

20.

Xu H, Zhang X, Mannon R, Kirk A . Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest. 2006; 116(3):769-74. PMC: 1378189. DOI: 10.1172/JCI27155. View